Novo Nordisk's SWOT analysis: obesity drug leader faces supply hurdles
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Hosted on MSN10h
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...
BioSpace12h
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Healio12h
About 31% of weight lost by adults during GLP-1 therapy comes from lean mass
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
thedailyupside16h
Novo Nordisk May Have Another Blockbuster on its Hands
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...